Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients with Cancer

Hidehiro Kaneko; Yuichiro Yano; Hokyou Lee; Hyeok Hee Lee; Akira Okada; Yuta Suzuki; Hidetaka Itoh; Satoshi Matsuoka; Katsuhito Fujiu; Nobuaki Michihata; Taisuke Jo; Norifumi Takeda; Hiroyuki Morita; Akira Nishiyama; Koichi Node; Hyeon Chang Kim; Hideo Yasunaga; Issei Komuro

doi:10.1200/JCO.22.00083

Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients with Cancer

Hidehiro Kaneko, Yuichiro Yano, Hokyou Lee, Hyeok Hee Lee, Akira Okada, Yuta Suzuki, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Koichi Node, Hyeon Chang Kim, Hideo Yasunaga, Issei Komuro

Department of Preventive Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

PURPOSEDespite the growing recognition of the importance of hypertension in patients with cancer, little is known about whether high blood pressure (BP) among patients with cancer is associated with incident heart failure (HF) and other cardiovascular disease (CVD) events and what BP levels are linked to these events. We examined the association of BP classification on the basis of the 2017 American College of Cardiology/American Heart Association BP guideline with the risk of HF and CVD events in patients with cancer.METHODSWe studied 33,991 patients with a history of breast, colorectal, or stomach cancer (median age, 53 years; 34.1% men). Patients receiving treatment with BP-lowering medications or having a history of CVD including HF were excluded. Using BP measurements at baseline, 33,991 participants were categorized as having normal BP (n = 17,444), elevated BP (n = 4,733), stage 1 hypertension (n = 7,502), or stage 2 hypertension (n = 4,312). The primary outcome was HF.RESULTSOver a mean follow-up of 2.6 ± 2.2 years, 779 HF events were recorded. After multivariable adjustment, the hazard ratios (HRs) for HF were 1.15 (95% CI, 0.93 to 1.44) for elevated BP, 1.24 (95% CI, 1.03 to 1.49) for stage 1 hypertension, and 1.99 (95% CI, 1.63 to 2.43) for stage 2 hypertension. A stepwise increase in risk with BP categories was also observed in other CVD events. This association was observed even in patients undergoing active cancer treatment. The relationship between hypertension and the risk of developing HF in patients with cancer was confirmed in the Korean National Health Insurance Service database.CONCLUSIONMedication-naïve stage 1 and 2 hypertension was associated with a greater risk of HF and other CVD events in patients with cancer. Our results suggest the importance of multidisciplinary collaboration (eg, oncologists and cardiologists) to establish the optimal management strategy for hypertension in patients with cancer.

Original language	English
Pages (from-to)	980-990
Number of pages	11
Journal	Journal of Clinical Oncology
Volume	41
Issue number	5
DOIs	https://doi.org/10.1200/JCO.22.00083
Publication status	Published - 2023 Feb 10

Bibliographical note

Funding Information:
Supported by grants from the Ministry of Health, Labour and Welfare, Japan (21AA2007 and 20AA2005), the Ministry of Education, Culture, Sports, Science and Technology, Japan (20H03907), and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HI19C1211).

Publisher Copyright:
© American Society of Clinical Oncology.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.22.00083

Cite this

Kaneko, H., Yano, Y., Lee, H., Lee, H. H., Okada, A., Suzuki, Y., Itoh, H., Matsuoka, S., Fujiu, K., Michihata, N., Jo, T., Takeda, N., Morita, H., Nishiyama, A., Node, K., Kim, H. C., Yasunaga, H., & Komuro, I. (2023). Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients with Cancer. Journal of Clinical Oncology, 41(5), 980-990. https://doi.org/10.1200/JCO.22.00083

@article{32a68a01dde343ac8ad3a751023959b3,

title = "Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients with Cancer",

abstract = "PURPOSEDespite the growing recognition of the importance of hypertension in patients with cancer, little is known about whether high blood pressure (BP) among patients with cancer is associated with incident heart failure (HF) and other cardiovascular disease (CVD) events and what BP levels are linked to these events. We examined the association of BP classification on the basis of the 2017 American College of Cardiology/American Heart Association BP guideline with the risk of HF and CVD events in patients with cancer.METHODSWe studied 33,991 patients with a history of breast, colorectal, or stomach cancer (median age, 53 years; 34.1% men). Patients receiving treatment with BP-lowering medications or having a history of CVD including HF were excluded. Using BP measurements at baseline, 33,991 participants were categorized as having normal BP (n = 17,444), elevated BP (n = 4,733), stage 1 hypertension (n = 7,502), or stage 2 hypertension (n = 4,312). The primary outcome was HF.RESULTSOver a mean follow-up of 2.6 ± 2.2 years, 779 HF events were recorded. After multivariable adjustment, the hazard ratios (HRs) for HF were 1.15 (95% CI, 0.93 to 1.44) for elevated BP, 1.24 (95% CI, 1.03 to 1.49) for stage 1 hypertension, and 1.99 (95% CI, 1.63 to 2.43) for stage 2 hypertension. A stepwise increase in risk with BP categories was also observed in other CVD events. This association was observed even in patients undergoing active cancer treatment. The relationship between hypertension and the risk of developing HF in patients with cancer was confirmed in the Korean National Health Insurance Service database.CONCLUSIONMedication-na{\"i}ve stage 1 and 2 hypertension was associated with a greater risk of HF and other CVD events in patients with cancer. Our results suggest the importance of multidisciplinary collaboration (eg, oncologists and cardiologists) to establish the optimal management strategy for hypertension in patients with cancer.",

author = "Hidehiro Kaneko and Yuichiro Yano and Hokyou Lee and Lee, {Hyeok Hee} and Akira Okada and Yuta Suzuki and Hidetaka Itoh and Satoshi Matsuoka and Katsuhito Fujiu and Nobuaki Michihata and Taisuke Jo and Norifumi Takeda and Hiroyuki Morita and Akira Nishiyama and Koichi Node and Kim, {Hyeon Chang} and Hideo Yasunaga and Issei Komuro",

note = "Funding Information: Supported by grants from the Ministry of Health, Labour and Welfare, Japan (21AA2007 and 20AA2005), the Ministry of Education, Culture, Sports, Science and Technology, Japan (20H03907), and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HI19C1211). Publisher Copyright: {\textcopyright} American Society of Clinical Oncology.",

year = "2023",

month = feb,

day = "10",

doi = "10.1200/JCO.22.00083",

language = "English",

volume = "41",

pages = "980--990",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "5",

}

Kaneko, H, Yano, Y, Lee, H, Lee, HH, Okada, A, Suzuki, Y, Itoh, H, Matsuoka, S, Fujiu, K, Michihata, N, Jo, T, Takeda, N, Morita, H, Nishiyama, A, Node, K, Kim, HC, Yasunaga, H & Komuro, I 2023, 'Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients with Cancer', Journal of Clinical Oncology, vol. 41, no. 5, pp. 980-990. https://doi.org/10.1200/JCO.22.00083

TY - JOUR

T1 - Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients with Cancer

AU - Kaneko, Hidehiro

AU - Yano, Yuichiro

AU - Lee, Hokyou

AU - Lee, Hyeok Hee

AU - Okada, Akira

AU - Suzuki, Yuta

AU - Itoh, Hidetaka

AU - Matsuoka, Satoshi

AU - Fujiu, Katsuhito

AU - Michihata, Nobuaki

AU - Jo, Taisuke

AU - Takeda, Norifumi

AU - Morita, Hiroyuki

AU - Nishiyama, Akira

AU - Node, Koichi

AU - Kim, Hyeon Chang

AU - Yasunaga, Hideo

AU - Komuro, Issei

N1 - Funding Information: Supported by grants from the Ministry of Health, Labour and Welfare, Japan (21AA2007 and 20AA2005), the Ministry of Education, Culture, Sports, Science and Technology, Japan (20H03907), and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HI19C1211). Publisher Copyright: © American Society of Clinical Oncology.

PY - 2023/2/10

Y1 - 2023/2/10

N2 - PURPOSEDespite the growing recognition of the importance of hypertension in patients with cancer, little is known about whether high blood pressure (BP) among patients with cancer is associated with incident heart failure (HF) and other cardiovascular disease (CVD) events and what BP levels are linked to these events. We examined the association of BP classification on the basis of the 2017 American College of Cardiology/American Heart Association BP guideline with the risk of HF and CVD events in patients with cancer.METHODSWe studied 33,991 patients with a history of breast, colorectal, or stomach cancer (median age, 53 years; 34.1% men). Patients receiving treatment with BP-lowering medications or having a history of CVD including HF were excluded. Using BP measurements at baseline, 33,991 participants were categorized as having normal BP (n = 17,444), elevated BP (n = 4,733), stage 1 hypertension (n = 7,502), or stage 2 hypertension (n = 4,312). The primary outcome was HF.RESULTSOver a mean follow-up of 2.6 ± 2.2 years, 779 HF events were recorded. After multivariable adjustment, the hazard ratios (HRs) for HF were 1.15 (95% CI, 0.93 to 1.44) for elevated BP, 1.24 (95% CI, 1.03 to 1.49) for stage 1 hypertension, and 1.99 (95% CI, 1.63 to 2.43) for stage 2 hypertension. A stepwise increase in risk with BP categories was also observed in other CVD events. This association was observed even in patients undergoing active cancer treatment. The relationship between hypertension and the risk of developing HF in patients with cancer was confirmed in the Korean National Health Insurance Service database.CONCLUSIONMedication-naïve stage 1 and 2 hypertension was associated with a greater risk of HF and other CVD events in patients with cancer. Our results suggest the importance of multidisciplinary collaboration (eg, oncologists and cardiologists) to establish the optimal management strategy for hypertension in patients with cancer.

AB - PURPOSEDespite the growing recognition of the importance of hypertension in patients with cancer, little is known about whether high blood pressure (BP) among patients with cancer is associated with incident heart failure (HF) and other cardiovascular disease (CVD) events and what BP levels are linked to these events. We examined the association of BP classification on the basis of the 2017 American College of Cardiology/American Heart Association BP guideline with the risk of HF and CVD events in patients with cancer.METHODSWe studied 33,991 patients with a history of breast, colorectal, or stomach cancer (median age, 53 years; 34.1% men). Patients receiving treatment with BP-lowering medications or having a history of CVD including HF were excluded. Using BP measurements at baseline, 33,991 participants were categorized as having normal BP (n = 17,444), elevated BP (n = 4,733), stage 1 hypertension (n = 7,502), or stage 2 hypertension (n = 4,312). The primary outcome was HF.RESULTSOver a mean follow-up of 2.6 ± 2.2 years, 779 HF events were recorded. After multivariable adjustment, the hazard ratios (HRs) for HF were 1.15 (95% CI, 0.93 to 1.44) for elevated BP, 1.24 (95% CI, 1.03 to 1.49) for stage 1 hypertension, and 1.99 (95% CI, 1.63 to 2.43) for stage 2 hypertension. A stepwise increase in risk with BP categories was also observed in other CVD events. This association was observed even in patients undergoing active cancer treatment. The relationship between hypertension and the risk of developing HF in patients with cancer was confirmed in the Korean National Health Insurance Service database.CONCLUSIONMedication-naïve stage 1 and 2 hypertension was associated with a greater risk of HF and other CVD events in patients with cancer. Our results suggest the importance of multidisciplinary collaboration (eg, oncologists and cardiologists) to establish the optimal management strategy for hypertension in patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=85140881705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140881705&partnerID=8YFLogxK

U2 - 10.1200/JCO.22.00083

DO - 10.1200/JCO.22.00083

M3 - Article

C2 - 36075006

AN - SCOPUS:85140881705

SN - 0732-183X

VL - 41

SP - 980

EP - 990

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 5

ER -

Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients with Cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this